Schedule Update - effective 1 September 2010 (text extract)

This is the text extract for Schedule Update - effective 1 September 2010, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 September 2010

Section H cumulative for August and September 2010

Contents

Summary of PHARMAC decisions effective 1 September 2010 ...................... 3 Atorvastatin – Subsidy changes ..................................................................... 6 Clopidogrel – removal of Special Authority criteria ....................................... 7 Meloxicam – new listing ................................................................................ 7 Zoledronic acid – new listing ......................................................................... 7 Sodium bicarbonate capsules – new listing ................................................... 7 Tenoxicam injection subsidised ...................................................................... 8 Travoprost – removal of endorsement period 30 September 2010 ................ 8 Amended Special Authority access for patients managed long-term on various NSAIDs ........................................................................ 8 Anaesthetics – subsidy changes .................................................................... 9 Anxiolytics, sedatives and hypnotics – removal of month restriction ............. 9 Ondansetron and tropisetron – restriction change ........................................ 9 News in brief ............................................................................................... 10 Tender News ................................................................................................ 11 Looking Forward ......................................................................................... 12 Sole Subsidised Supply products cumulative to September 2010................ 14 New Listings ................................................................................................ 21 Changes to Restrictions ............................................................................... 24 Changes to Subsidy and Manufacturer’s Price............................................. 32 Changes to General Rules............................................................................ 35 Changes to Brand Name ............................................................................. 35 Changes to Section E Part I ......................................................................... 35 Changes to Sole Subsidised Supply ............................................................. 35 Delisted Items ............................................................................................. 36 Items to be Delisted .................................................................................... 38 Section H changes to Part II ........................................................................ 39 Section H changes to Part III........................................................................ 43 Index ........................................................................................................... 44

Summary of PharmaC decisions

effeCtive 1 SePtemBer 2010 New listings (pages 21-23) • Insulin glulisine (Apidra) inj 100 u per ml, 3 ml • Mucilaginous laxatives (Konsyl-D) dry 500 g OP – Only on a prescription • Vitamin B complex (B-PlexADE) tab, strong BPC • Clopidogrel (Apo-Clopidogrel) tab 75 mg, 90 cap pack • Sodium bicarbonate (Sodibic) cap 840 mg • Furosemide (Frusemide-Claris) inj 10 mg per ml, 2 ml – Up to 5 inj available on a PSO • Ceftriaxone sodium (Veracol) inj 500 mg – Subsidy by endorsement – Up to 5 inj available on a PSO • Cephalexin (Cephalexin ABM) cap 500 mg • Meloxicam (Arrow-Meloxicam) tab 7.5 mg – Special Authority – Retail pharmacy • Tenoxicam (AFT) inj 20 mg • Zoledronic acid (Aclasta) soln for infusion 5 mg in 100 ml – Special Authority – Retail pharmacy • Lignocaine hydrochloride (Xylocaine) inj 2%, 5 ml and 20 ml – Up to 5 inj available on a PSO • Lignocaine hydrochloride (Xylocaine Viscous) Viscous solution 2%, 200 ml • Cyclizine lactate (Nausicalm) inj 50 mg per ml, 1 ml • Fluorouracil sodium (Baxter) inj 1 mg for ECP, 100 mg – PCT only – Specialist • Mesna (Baxter) inj 1 mg for ECP, 100 mg – PCT only – Specialist • Sodium cromoglycate (Rexacrom) eye drops 2%, 5 ml OP Changes to restrictions (pages 24-31) • Acarbose (Glucobay) tab 50 mg and 100 mg – removal of Special Authority criteria • Pioglitazone (Pizaccord) tab 15 mg, 30 mg and 45 mg – amended Special Authority criteria • Multivitamins (Paediatric Seravit) powder – amended Special Authority criteria • Clopidogrel (Apo-Clopidogrel, Arrow-Clopidogrel, Plavix) tab 75 mg – removal of Special Authority criteria • Atorvastatin (Lipitor) tab 10 mg, 20 mg, 40 mg and 80 mg – removal of Special Authority criteria • Amiloride with hydrochlorothiazide (Moduretic) tab 5 mg with hydrochlorothiazide 50 mg – removal of Section 29 • Isotretinoin (Oratane) cap 10 mg and 20 mg – amended Special Authority criteria

Summary of PharmaC decisions – effective 1 September 2010 (continued) • Triclosan (healthE) soln 1% – addition of Original Pack • Malathion (A-Lices) liq 0.5% – addition of Original Pack • Azithromycin (Arrow-Azithromycin) tab 500 mg – increased quantity available on a PSO • Ethambutol hydrochloride (Myambutol) tab 100 mg and 400 mg – removal of Section 29 • Interferon alpha-2A (Roferon-A) inj prefilled syringe 3 m iu, 6 m iu and 9 m iu – removal of prescribing note • Anti-inflammatory Non Steroidal Drugs (NSAIDS) – removal of Special Authority criteria (except for patients with existing approvals) • Alendronate sodium (Fosamax) tab 70 mg - amended Special Authority criteria • Alendronate sodium with cholecalciferol (Fosamax Plus) tab 70 mg with cholecalciferol 5,600 iu – amended Special Authority criteria • Lignocaine (Pfizer) gel 2%, 10 ml urethral syringe – Up to 5 each available on a PSO • Lignocaine hydrochloride (Xylocaine) inj 0.5%, 5 ml, inj 1%, 5 ml and inj 1%, 20 ml – removal of prescribing restriction • Lignocaine with chlorohexidine (Pfizer) gel 2% with chlorohexidine 0.05%, 10 ml urethral syringes – Up to 5 each available on a PSO • Ondansetron tab 4 mg and 8 mg (Zofran) and tab disp 4 mg and 8 mg (Zofran Zydis) – removal of Retail pharmacy – Specialist • Tropisetron (Navoban) cap 5 mg – removal of Retail pharmacy – Specialist • Alprazolam (Arrow-Alprazolam) tab 250 µg, 500 µg and 1 mg – removal of Month Restriction • Buspirone hydrochloride (Pacific Buspirone) tab 5 mg and 10 mg – removal of Month Restriction • Diazepam (Arrow-Diazepam) tab 2 mg and 5 mg – removal of Month Restriction • Lorazepam (Ativan) tab 1 mg and 2.5 mg – removal of Month Restriction • Oxazepam (Ox-Pam) tab 10 mg and 15 mg – removal of Month Restriction • Lormetazepam (Noctamid) tab 1 mg – removal of Month Restriction • Midazolam (Hypnovel) tab 7.5 mg – removal of Month Restriction • Nitrazepam (Nitrados) tab 5 mg – removal of Month Restriction • Temazepam (Normison) tab 10 mg – removal of Month Restriction • Triazolam (Hypam) tab 125 µg and 250 µg – removal of Month Restriction • Zopiclone (Apo-Zopiclone) tab 7.5 mg – removal of Month Restriction • Capecitabine (Xeloda) tab 150 mg and 500 mg – amended Special Authority criteria

Summary of PharmaC decisions – effective 1 September 2010 (continued) Decreased subsidy (pages 32-34) • Clopidogrel (Apo-Clopidogrel) tab 75 mg, 28 tab pack • Amiloride with hydrochlorothiazide (Moduretic) tab 5 mg with hydrochlorothiazide 50 mg • Coal tar (David Craig) soln BP • Sodium citro-tartrate (Ural) grans eff 4 g sachets • Ethambutol hydrochloride (Myambutol) tab 100 mg and 400 mg • Lignocaine hydrochloride (Xylocaine) inj 1%, 5 ml and 20 ml • Morphine sulphate (m-Eslon) cap long-acting 60 mg • Gabapentin (Neurontin) tab 600 mg, and cap 100 mg, 300 mg and 400 mg • Fluorouracil sodium (Fluorouracil Ebewe) inj 50 mg per ml, 20 ml, 50 ml and 100 ml • Glycerol (PSM, ABM, Midwest) liquid increased subsidy (pages 32-34) • Sodium chloride (Biomed) inj 23.4%, 20 ml • Atorvastatin (Lipitor) tab 10 mg, 20 mg, 40 mg, and 80 mg • Captopril (Capoten) oral liq 5 mg per ml, 95 ml OP • Hydrocortisone (Solu-Cortef) inj 50 mg per ml, 2 ml • Phenoxymethylpenicillin (Cilicaine VK) cap potassium salt 250 mg and 500 mg • Nystatin (Nilstat) tab 500,000 u and cap 500,000 u • Ibuprofen (Brufen Retard) tab long-acting 800 mg • Lignocaine with prilocaine (EMLA) crm 2.5% with prilocaine 2.5%, 30 g OP and 5 g tubes • Morphine sulphate (m-Eslon) cap long-acting 10 mg, 30 mg and 100 mg • Morphine tartrate (Hospira) inj 80 mg per ml, 1.5 ml and 5 ml • Haloperidol (Serenace) tab 500 µg, 1.5 mg, 5 mg; oral liq 2 mg per ml, 100 ml; and inj 5 mg per ml, 1 ml • Fluorouracil sodium (Fluorouracil Ebewe) inj 50 mg per ml, 10 ml • Methotrexate inj 25 mg per ml, 2 ml and 20 ml (Hospira) and inj 1 mg for ECP (Baxter) • Dacarbazine inj 200 mg (Hospira), inj 200 mg for ECP (Baxter) • Mesna (Uromitexan) tab 400 mg, 600 mg and inj 100 mg per ml, 4 ml and 10 ml • Flutamide (Flutamin) tab 250 mg • Nedocromil (Tilade) aerosol inhaler, 2 mg per dose CFC-free • Sodium cromoglycate powder for inhalation 20 mg per dose (Intal Spincaps) and aerosol inhaler, 5 mg per dose CFC-free (Vicrom) • Theophylline (Nuelin) oral liq 80 mg per 15 ml

6 Pharmaceutical Schedule - Update News

Atorvastatin – subsidy changes

PHARMAC and Pfizer New Zealand Ltd have reached an agreement to continue to list Pfizers brand of atorvastatin tablets (Lipitor). From 1 September 2010 Lipitor will be fully subsidised without Special Authority. The subsidy will increase to match the manufacturer’s price which means that patients can access fully subsidised atorvastatin without restriction from 1 September 2010. Lipitor will have subsidy and delisting protection until 31 August 2012. For the avoidance of doubt, the agreement with Pfizer is not for sole subsidised supply. Following a competitive process, Mylan New Zealand’s brand of atorvastatin (Lorstat) was to be the sole subsidised supply brand of atorvastatin from 1 December 2010 for community supply. Mylan was not able to release stock to the

market on 26 July 2010 as initially notified, and the timing of Lorstats availability was uncertain. PHARMAC has agreed with Mylan that Lorstat will no longer have Sole Subsidised Supply Status and will be delisted from the Pharmaceutical Schedule from 1 September 2010. PHARMAC regrets any disruptions caused to patients, doctors and pharmacists by the uncertainty over the supply date of Lorstat.

Pharmaceutical Schedule - Update News

Clopidogrel – removal of Special Authority criteria

The Special Authority for subsidised access to clopidogrel tablets 75 mg will be removed from 1 September 2010. This will mean that from 1 September 2010 all patients prescribed clopidogrel 75 mg tablets will be eligible for subsidy and that Special Authority approvals are no longer required. This decision widens access to clopidogrel 75 mg tablets to aspirin intolerant patients, stroke and transient ischaemic attack patients as an alternative to aspirin or dipyridamole combination therapy and provides extended treatment (12 months) for patients following a revascularisation procedure or acute coronary syndrome.

Meloxicam – new listing

The Arrow-Meloxicam brand of meloxicam 7.5 mg tablets will be fully subsidised from 1 September 2010. Subsidy will be subject to Special Authority criteria restricting funding to patients with moderate to severe haemophilia and pain and inflammation associated with haemophilic arthropathy where alternative funded treatment options have failed or are contraindicated.

Zoledronic acid – new listing

Zoledronic acid (Aclasta) solution for infusion 5 mg in 100 ml for Paget’s disease and osteoporosis (including glucocorticosteroid-induced osteoporosis) will be subsidised from 1 September 2010. Subsidy will be subject to Special Authority criteria. See page 21 for further details. The Special Authority criteria for Alendronate for Osteoporosis (Fosamax and Fosamax Plus) will also be amended from 1 September 2010 to enable patients who receive an approval for zoledronic acid to be able to access alendronate.

Sodium bicarbonate capsules – new listing

Sodium bicarbonate (Sodibic) 840 mg capsules will be listed fully subsidised from 1 September 2010 without restriction. Sodium bicarbonate is used in the treatment of metabolic acidosis associated with chronic renal failure.

Pharmaceutical Schedule - Update News

Tenoxicam injection subsidised

The AFT brand of tenoxicam 20 mg injection will be fully subsidised from 1 September 2010, without restriction. This product replaces a previously subsidised brand that was discontinued by its supplier in 2008.

Travoprost – removal of endorsement period 30 September 2010

From 1 April 2010 the subsidy for travoprost (Travatan) eye drops 0.004% was reduced to match that of latanoprost eye drops 50 µg per ml, 2.5 ml (Hysite). For patients taking travoprost eye drops prior to 1 April 2010 a full subsidy is available under endorsement criteria until 30 September 2010. Patients only have one month remaining on this endorsement period. This six month transition period was provided to allow patients sufficient time to return to their ophthalmologist for a review of their medication if they wished to switch to a fully subsidised alternative.

Amended Special Authority access for patients managed long-term on various NSAIDs

All valid approvals for the Special Authority for Manufacturers Price applying to Antiinflammatory Non Steroidal Drugs (NSAIDs) at 31 August 2010 will be converted to lifetime approvals. No new Special Authority approvals for Manufacturers Price will be granted for NSAIDs from 1 September 2010. In a separate decision, the subsidy of ibuprofen 800 mg long-acting tablets (Brufen Retard) will be increased to match the manufacturer’s price from 1 September 2010, resulting in this presentation becoming fully subsidised.

Pharmaceutical Schedule - Update News

Anaesthetics – subsidy changes

There will be a number of changes to the listings of local anaesthetics from 1 September 2010, summarised as follows: • Lignocaine hydrochloride viscous solution 2% (Xylocaine Viscous) will be fully subsidised without restriction. • Lignocaine hydrochloride injection 2%, 5 ml and 20 ml (Xylocaine), will be fully subsidised without restriction. • The “only if prescribed on prescription for a dialysis patient or child with rheumatic fever or on a PSO for emergency use” restriction will be removed from the listings of lignocaine hydrochloride injection 0.5% 5 ml, and 1% 5 ml and 20 ml (Xylocaine). • Lignocaine gel 2%, 10 ml urethral syringe (Pfizer) and lignocaine gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe (Pfizer) will be subsidised on a PSO with a maximum of 5 syringes subsidised. • Lignocaine hydrochloride injection 0.5% 5 ml, 1% 5 ml and 20 ml and 2% 5 ml and 20 ml (Xylocaine) will be subsidised on a PSO with a maximum of 5 injections subsidised. • Bupivacaine hydrochloride injection 0.5%, 4 ml (Marcain Isobaric) and injection 0.5% with 8% glucose, 4 ml (Marcain Heavy) will be delisted from Section B of the Pharmaceutical Schedule.

Anxiolytics, sedatives and hypnotics – removal of month restriction

The ‘Month Restriction’ that currently applies to most anxiolytics, sedatives and hypnotics will be removed from 1 September 2010. This will result in repeat dispensings for these medicines being subsidised, where currently they are not. However, monthly dispensing will still apply.

Ondansetron and tropisetron – restriction change

The ‘Retail pharmacySpecialist’ restrictions will be removed from the listings of ondansetron tablets (Zofran) and dispersible tablets (Zofran Zydis), and tropisetron capsules (Navoban), from 1 September 2010. The other dispensing rules applying to both ondansetron and tropisetron will remain and the Special Authority for waiver of the dispensing rules for ondansetron will also remain. (Note that PHARMAC has also made the decision to remove the dispensing rules from ondansetron from 1 May 2011, and Special Authority to waive these restrictions will also be removed from 1 May 2011 as it would no longer be relevant.)

10 Pharmaceutical Schedule - Update News

News in brief

• Mylan New Zealand Limited has notified its intention to discontinue its brand of labetalol (Hybloc) 400 mg tablets in September 2010. The 50 mg, 100 mg, and 200 mg tablets will continue to be supplied. • The 4 tablet limit for azithromycin (ArrowAzithromycin) 500 mg tablets available on a Practitioner Supply Order (PSO) will be increased to 8 tablets from 1 September 2010. • Triclosan (healthE) 1% solution will be able to be claimed as original packs (OP’s) from 1 September 2010. Malathion liquid 0.5% (A-Lices) will also be able to be claimed as original packs (OP’s) from 1 September 2010. • The fluorouracil sodium (Baxter) injection for ECP pack size has been amended from 1 mg to 100 mg from 1 September 2010. A new pharmacode (2370123) has

been issued for this pack size. The mesna (Baxter) injection for ECP pack size has also been amended from 1 mg to 100 mg from 1 September 2010. A new pharmacode (2370131) has been issued for this pack size. • The Donepezil-Rex brand of donepezil hydrochloride 5 mg and 10 mg tablets is now approved and will be listed in the Pharmaceutical Schedule on 1 November 2010.

tender News

Sole Subsidised Supply changes – effective 1 October 2010

Chemical Name Aspirin Aspirin Bendrofluazide Bendrofluazide Bisacodyl Cefaclor monohydrate Cetomacrogol Clotrimazole Clotrimazole Colchicine Cyclophosphamide Dexamethasone Dextrose with electrolytes Presentation; Pack size Tab 100 mg; 990 tab Tab dispersible 300 mg; 100 tab Tab 2.5 mg; 500 tab Tab 5 mg; 500 tab Tab 5 mg; 200 tab Grans for oral liq 125 mg per 5 ml; 100 ml Crm BP; 500 g Vaginal crm 1% with applications; 35 g OP Vaginal crm 2% with applications; 35 g OP Tab 500 µg; 100 tab Tab 50 mg; 50 tab Eye drops 0.1%; 5 ml OP Soln with electrolytes; 1,000 ml OP Sole Subsidised Supply brand (and supplier) Ethics Aspirin EC (Multichem) Ethics Aspirin (Multichem) Arrow-Bendrofluazide (Arrow) Arrow-Bendrofluazide (Arrow) Lax-Tab (AFT) Ranbaxy-Cefaclor (Douglas) PSM (API) Clomazol (Multichem) Clomazol (Multichem) Colgout (Aspen) Cycloblastin (Pfizer) Maxidex (Alcon) Pedialyte – Fruit (Abbott) Pedialyte – Bubblegum (Abbott) Pedialyte – Plain (Abbott) Ferodan (Mylan) Fluox (Mylan) Foban (AFT) Foban (AFT) Micreme H (Mylan) Fenpaed (AFT) Lorapaed (AFT) Loraclear Hayfever Relief (AFT) A-Lices (AFT) Dr Reddy's Pantoprazole (Dr Reddy's) Dr Reddy's Pantoprazole (Dr Reddy's) Lacri-Lube (Allergan) Loxamine (Mylan) AFT (AFT) AFT (AFT)

Ferrous sulphate Fluoxetine hydrochloride Fusidic acid Fusidic acid Hydrocortisone with miconazole Ibuprofen Loratadine Loratadine Malathion Pantoprazole Pantoprazole Paraffin liquid with soft white paraffin Paroxetine hydrochloride Phenoxymethylpenicillin (Penicillin V) Phenoxymethylpenicillin (Penicillin V)

Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml); 500 ml Tab dispersible 20 mg, scored Crm 2%; 15 g OP Oint 2%; 15 g OP Crm 1% with miconazole nitrate 2%; 15 g OP Oral liq 100 mg per 5 ml; 200 ml Oral liq 1 mg per ml; 100 ml Tab 10 mg; 100 tab Shampoo 1%; 30 ml OP Tab 20 mg; 28 tab Tab 40 mg; 28 tab Eye oint with soft white paraffin; 3.5 g OP Tab 20 mg; 30 tab Grans for oral liq 125 mg per 5 ml; 100 ml Grans for oral liq 250 mg per 5 ml; 100 ml

Sole Subsidised Supply changes – effective 1 October 2010 (continued)

Rifabutin Ropinirole hydrochloride Ropinirole hydrochloride Ropinirole hydrochloride Ropinirole hydrochloride Salbutamol Spironolactone Spironolactone Testosterone undecanoate Cap 150 mg; 30 cap Tab 0.25 mg; 84 tab Tab 1 mg; 84 tab Tab 2 mg; 84 tab Tab 5 mg; 84 tab Oral liq 2 mg per 5 ml; 150 ml Tab 25 mg; 100 tab Tab 100 mg; 100 tab Cap 40 mg; 100 cap Mycobutin (Pfizer) Ropin (Mylan) Ropin (Mylan) Ropin (Mylan) Ropin (Mylan) Salapin (AFT) Spirotone (Mylan) Spirotone (Mylan) Arrow-Testosterone (Arrow)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for implementation 1 October 2010 • Adapalene (Differin) crm 0.1%, 30 g OP and gel 0.1%, 30 g OP – new listing, maximum of 30 g per prescription, only on a prescription • Anastrozole (Aremed) tab 1 mg – new listing • Budesonide (Budenocort) powder for inhalation 200 µg per dose and 400 µg per dose – new listing • Capecitabine (Xeloda) – amended Special Authority criteria • Deferiprone (Ferriprox) tab 500 mg and oral soln 100 mg per ml, 250 ml – new listing – Special Authority – Retail pharmacy • Elemental formula 1 kcal/ml (Elecare) powder (unflavoured) 400 g OP and powder (vanilla) 400 g OP – new listing under existing Special Authority criteria • Elemental formula 1 kcal/ml (Elecare LCP) powder (unflavoured) 400 g OP – new listing under existing Special Authority criteria • Elemental formula 1 kcal/ml (Neocate) powder 400 g OP and (Neocate LCP) powder 400 g OP – decrease subsidy • Enteral feed with fibre 1 kcal/ml (Jevity) liquid 237 ml OP – new listing under existing Special Authority criteria • Enteral feed with fibre 1 kcal/ml (Jevity RTH) liquid 500 ml OP – new listing under existing Special Authority criteria • Enteral feed with fibre 1.5 kcal/ml (Ensure Plus) liquid 250 ml OP – new listing under existing Special Authority criteria

Possible decisions for implementation 1 October 2010 (continued) • Enteral feed 1 kcal/ml (Osmolite) liquid 250 ml OP – new listing under existing Special Authority criteria • Enteral feed 1 kcal/ml (Osmolite RTH) liquid 500 ml OP – new listing under existing Special Authority criteria • Erlotinib hydrochloride (Tarceva) tab 100 mg and 150 mg – new listing – Special Authority – Retail pharmacy • Ezetimibe (Ezetrol) tab 10 mg – amended Special Authority criteria • Ezetimibe with simvastatin (Vytorin) tab –amended Special Authority criteria • Mianserin hydrochloride (Tolvon) – amended Special Authority criteria – price and subsidy decrease • Mycophenolate mofetil (Cellcept) cap 250 mg and tab 500 mg – amended Special Authority criteria – price and subsidy decrease • Mycophenolate mofetil (Myaccord) cap 250 mg and tab 500 mg – new listing • Oestriol (Ovestin) tab 2 mg, pessaries 500 µg, and crm 1 mg per g with applicator – price and subsidy decrease • Oral supplement 1 kcal/ml (Ensure NG) powder 400 g OP (vanilla) and 900 g OP (vanilla and chocolate) – new listing under existing Special Authority criteria • Oral supplement 1 kcal/ml (Ensure) powder (chocolate, strawberry and vanilla) 400 g OP – subsidy and price decrease • Oral supplement 1 kcal/ml (Sustagen Hospital Formula) powder (chocolate) 900 g OP and powder (Vanilla) 900 g OP – decrease subsidy • Paediatric oral feed 1 kcal/ml (Pediasure) liquid (vanilla) 200 ml OP – new listing under existing Special Authority criteria • Quetiapine (Seroquel) tab 25 mg, 100 mg, 200 mg and 300 mg – decrease subsidy • Renal oral feed 2 kcal/ml (Nepro) liquid (strawberry) 200 ml OP – new listing under existing Special Authority criteria • Rituximab (Mabthera) inj – amended Special Authority criteria • Tenofovir disoproxil fumarate (Viread) tab 300 mg – amended Special Authority criteria • Travoprost (Travatan) eye drops 0.004% – removal of higher subsidy with endorsement • Urea (Nutraplus) crm 10% 100 g OP – subsidy increase

Sole Subsidised Supply Products – cumulative to September 2010

Generic Name

Acarbose Acetazolamide Allopurinol Amantadine hydrochloride Amoxycillin

Presentation

Tab 50 mg & 100 mg Tab 250 mg Tab 100 mg & 300 mg Cap 100 mg Grans for oral liq 250 mg per 5 ml Drops 125 mg per 1.25 ml Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab amoxycillin 500 mg with potassium clavulanate 125 mg Crm 500 g Tab 50 mg & 100 mg Inj 600 µg, 1 ml Tab 500 mg Tab 10 mg Inj 1 mega u Scalp app 0.1% Tab 200 mg Tab 50 mg Eye drops 0.2% Crm, aqueous, BP Lotn, BP Inj 100 iu per ml, 1 ml Cap 0.25 µg & 0.5 µg Tab eff 1.7 g (1 g elemental) Inj 50 mg Inj 500 mg & 1 g Inj 750 mg & 1.5 g Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 10 mg Oral liq 1 mg per ml Eye oint 1%

Brand Name Expiry Date*

Glucobay Diamox Apo-Allopurinol Symmetrel Ospamox Ospamox Paediatric Drops Curam Curam Synermox AFT Atenolol Tablet USP AstraZeneca Arrow-Azithromycin Pacifen Sandoz Beta Scalp Fibalip Bicalox AFT healthE API Miacalcic Airflow Calsource Calcium Folinate Ebewe Hospira Zinacef Cefalexin Sandoz Cefalexin Sandoz Zetop Cetirizine-AFT Chlorsig 2011 2011 2012 2012 2012 2012 2011 2012 2011 2011 2011 2012 2011 2012 2011 2011 2011 2011 2012 2011 2012 2012 2011 2011 2011 2012 2011 2012

Amoxycillin clavulanate

Aqueous cream Atenolol Atropine sulphate Azithromycin Baclofen Benzylpenicillin sodium (Penicillin G) Betamethasone valerate Bezafibrate Bicalutamide Brimonidine tartrate Calamine Calcitonin Calcitriol Calcium carbonate Calcium folinate Cefazolin sodium Cefuroxime sodium Cephalexin monohydrate Cetirizine hydrochloride Chloramphenicol

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to September 2010

Generic Name

Chlorhexidine gluconate Ciclopiroxolamine Ciprofloxacin Citalopram Clobetasol propionate

Presentation

Handrub 1% with ethanol 70% Soln 4% Nail soln 8% Tab 250 mg, 500 mg & 750 mg Tab 20 mg Crm 0.05% Oint 0.05% Scalp app 0.05% Tab 500 µg & 2 mg TDDS 2.5 mg, 100 µg per day TDDS 5 mg, 200 µg per day TDDS 7.5 mg, 300 µg per day Inj 150 µg per ml, 1 ml Tab 25 µg Tab 150 µg Crm 1% Crm 10% Tab 50 mg Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs Nasal spray 10 µg per dose Inj 4 mg per ml, 1 ml & 2 ml Inj 50%, 10 ml Tab EC 25 mg & 50 mg Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab long-acting 60 mg Tab 30 mg & 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab long-acting 150 mg Cap 50 mg Cap 120 mg Tab 50 mg with total sennosides 8 mg Oint BP

Brand Name Expiry Date*

healthE Orion Batrafen Rex Medical Arrow-Citalopram Dermol Dermol Dermol Paxam Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3 Catapres Dixarit Catapres Clomazol Itch-Soothe Nausicalm Siterone Ginet 84 Desmopressin-PH&T Hospira Biomed Diclofenac Sandoz Voltaren Ophtha Voltaren Voltaren DHC Continus Dilzem Cardizem CD Pytazen SR Laxofast 50 Laxofast 120 Laxsol AFT 2012 2011 2012 2011 2011 2012

Clonazepam Clonidine

2011 2012

Clonidine hydrochloride

2012

Clotrimazole Crotamiton Cyclizine hydrochloride Cyproterone acetate Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone sodium phosphate Dextrose Diclofenac sodium

2011 2012 2012 2012 2011 2011 2013 2011 2012 2011

Dihydrocodeine tartrate Diltiazem hydrochloride

2013 31/12/11

Dipyridamole Docusate sodium Docusate sodium with sennosides Emulsifying ointment

2011 2011 2013 2011

Sole Subsidised Supply Products – cumulative to September 2010

Generic Name

Enoxaparin sodium (low molecular weight heparin) Entacapone Erythromycin ethyl succinate

Presentation

Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Tab 10 µg Tab 200 mg Tab long-acting 5 mg Tab long-acting 10 mg Tab 5 mg Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Inj 50 mg Tab 10 mg Eye drops 0.1% Metered aqueous nasal spray, 50 µg per dose Tab 40 mg Cap 100 mg, 300 mg & 400 mg Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Tab 600 µg Oral pump spray 400 µg per dose TDDS 5 mg & 10 mg

Brand Name Expiry Date*

Clexane Comtan E-Mycin E-Mycin E-Mycin NZ Medical and Scientific Arrow-Etidronate Felo 5 ER Felo 10 ER Fintral AFT AFT AFT Flucloxin Pacific Fludara Fludara Oral FML Flixonase Hayfever & Allergy Diurin 40 Nupentin Pfizer Apo-Gliclazide Minidiab Lycinate Nitrolingual Pumpspray Nitroderm TTS Douglas ABM PSM Colifoam DP Lotn HC ABM Hydroxocobalamin Plaquenil 2012 2012 2012 2011 2012 2012 2012 2011 2012 2011 2011 2011 2012 31/1/13 2012 31/7/12 2012 2011 2011 2011

Ethinyloestradiol Etidronate disodium Felodipine Finasteride Flucloxacillin sodium

Fluconazole Fludarabine phosphate Fluorometholone Fluticasone propionate Furosemide Gabapentin Gentamicin sulphate Gliclazide Glipizide Glyceryl trinitrate

Hydrocortisone

Tab 5 mg & 20 mg Powder Crm 1% Rectal foam 10%, CFC-free (14 applications) Lotn 1% with wool fat hydrous 3% and mineral oil Inj 1 mg per ml, 1 ml Tab 200 mg

2012 2011 2012 2011 2012 2012

Hydrocortisone acetate Hydrocortisone with wool fat and mineral oil Hydroxocobalamin Hydroxychloroquine sulphate

Sole Subsidised Supply Products – cumulative to September 2010

Generic Name

Hypromellose Hysocine N-butylbromide Ibuprofen Iron polymaltose Isotretinoin Ketoconazole Lamivudine Latanoprost Letrozole Levonorgestrel Lisinopril Malathion Mask for Spacer Device Mebendazole Mebeverine hydrochloride Megestrol acetate Mesalazine Metformin hydrochloride Methadone hydrochloride

Presentation

Eye drops 0.5% Inj 20 mg, 1 ml Tab 20 mg Tab 200 mg Inj 50 mg per ml, 2 ml Cap 10 mg & 20 mg Shampoo 2% Oral liq 10 mg per ml Tab 150 mg Eye drops 50 µg per ml Tab 2.5 mg Subdermal implant (2 x 75 mg rods) Tab 5 mg, 10 mg & 20 mg Shampoo 1% Device Tab 100 mg Tab 135 mg Tab 160 mg Enema 1 g per 100 ml Tab immediate-release 500 mg & 850 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 2.5 mg & 10 mg Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml Tab 125 mg, 250 mg & 500 mg Tab 4 mg & 100 mg Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g Inj 5 mg per ml, 2 ml Crm 2%

Brand Name Expiry Date*

Methopt Buscopan Gastrosoothe Ethics Ibuprofen Ferrum H Oratane Sebizole 3TC 3TC Hysite Letara Jadelle Arrow-Lisinopril A-Lices Foremount Child’s Silicone Mask De-Worm Colofac Apo-Megestrol Pentasa Apotex Biodone Biodone Forte Biodone Extra Forte Methoblastin Methotrexate Ebewe Methotrexate Ebewe Prodopa Medrol Depo-Medrol Depo-Medrol with Lidocaine Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Multichem 2011 2011 2012 2011 2012 2011 2013 2012 2012 31/12/13 2012 2011 30/9/11 2011 2011 2012 2012 2012 2012

Methotrexate

2012 2011 2011 2012 2011 2011 2012

Methyldopa Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Methylprednisolone sodium succinate

Metoclopramide hydrochloride Miconazole nitrate

2011 2011

Sole Subsidised Supply Products – cumulative to September 2010

Generic Name

Mometasone furoate Morphine hydrochloride

Presentation

Crm 0.1% Oint 0.1% Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab immediate release 10 mg & 20 mg Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Tab 250 mg Tab 500 mg Oral suspension 10 mg per ml Tab 200 mg

Brand Name Expiry Date*

m-Mometasone m-Mometasone RA-Morph RA-Morph RA-Morph RA-Morph Sevredol Mayne Mayne Noflam 250 Noflam 500 Viramune Suspension Viramune Noriday 28 Primolut N Norpress Nilstat Dr Reddy’s Omeprazole Dr Reddy’s Omeprazole Syntocinon Syntocinon Syntometrine Pamisol Pamisol Pamisol Pharmacare Paracare Junior Paracare Double Strength ParaCode Breath-Alert Pegasys Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack 2012 2012

Morphine sulphate

2012 2011 2012 2012

Naproxen Nevirapine

Norethisterone Nortriptyline hydrochloride Nystatin Omeprazole

Tab 350 µg Tab 5 mg Tab 10 mg & 25 mg Oral liq 100,000 u per ml, 24 ml OP Cap 10 mg, 20 mg & 40 mg Inj 40 mg

2012 2011 2011 2011 2011

Oxytocin

Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Low range and Normal range Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168

2012

Pamidronate disodium

2011

Paracetamol

2011

Paracetamol with codeine Peak Flow Meter Pegylated interferon alpha-2A

2011 30/9/11 31/12/12

Sole Subsidised Supply Products – cumulative to September 2010

Generic Name

Pergolide Permethrin Pindolol Pioglitazone Pizotifen Poloxamer Polyvinyl alcohol Potassium chloride Prednisone Prednisone sodium phosphate Pregnancy tests – hCG urine Procaine penicillin Promethazine hydrochloride

Presentation

Tab 0.25 mg & 1 mg Lotn 5% Tab 5 mg, 10 mg & 15 mg Tab 15 mg, 30 mg & 45 mg Tab 500 µg Oral drops 10% Eye drops 1.4% Eye drops 3% Tab long-acting 600 mg Tab 1 mg, 2.5 mg, 5 mg & 20 mg Oral liq 5 mg per ml Cassette Inj 1.5 mega u Oral liq 5 mg per 5 ml Tab 10 mg & 25 mg

Brand Name Expiry Date*

Permax A-Scabies Apo-Pindolol Pizaccord Sandomigran Coloxyl Vistil Vistil Forte Span-K Apo-Prednisone Redipred Innovacon hCG One Step Pregnancy Test Cilicaine Promethazine Winthrop Elixir Allersoothe Accupril Accuretic 10 Accuretic 20 Q 300 ArrowRoxithromycin Asthalin Asthalin Duolin 2012 2012 2012 2012 2011 2011 2012 2012 2012 2011 2011 2012 2011 2012 2012 2011 2012 2011 2011 2011

Quinapril Quinapril with hydroclorothiazide

Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydroclorothiazide 12.5 mg Tab 20 mg with hydroclorothiazide 12.5 mg Tab 300 mg Tab 150 mg & 300 mg Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratopium bromide 0.5 mg per vial, 2.5 ml Tab 5 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Nasal spray, 4% Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) Tab 80 mg & 160 mg 230 ml Tab 50 mg & 100 mg

Quinine sulphate Roxithromycin Salbutamol Salbutamol with ipratropium bromide Selegiline hydrochloride Simvastatin

Apo-Selegiline Arrow-Simva 10 mg Arrow-Simva 20 mg Arrow-Simva 40 mg Arrow-Simva 80 mg Rex Genotropin Genotropin Mylan Space Chamber Arrow-Sumatriptan

2012 2011

Sodium cromoglycate Somatropin Sotalol Spacer Device Sumatriptan

2012 31/12/12 2012 30/9/11 2013

Sole Subsidised Supply Products – cumulative to September 2010

Generic Name

Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terbinafine Testosterone cypionate Tetracosactrin Timolol maleate Tramadol hydrochloride Tranexamic acid Triamcinolone acetonide

Presentation

Soln 2.3% Tab 10 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Inj 250 µg Inj 1 mg per ml, 1 ml Tab 10 mg Eye drops 0.25% & 0.5% Cap 50 mg Tab 500 mg Crm 0.02% Oint 0.02% Inj 40 mg per ml, 1 ml 0.1% in Dental Paste USP Tab 300 mg Cap 5 mg Cap 300 mg Inj 50 mg per ml, 10 ml Cap 100 mg Oral liq 10 mg per ml Oint BP Cap 137.4 mg (50 mg elemental) Tab 7.5 mg

Brand Name Expiry Date*

Pinetarsol Normison Apo-Terbinafine Depo-Testosterone Synacthen Synacthen Depot Apo-Timol Apo-Timop Arrow-Tramadol Cycklokapron Aristocort Aristocort Kenacort-A40 Oracort TMP Navoban Actigall Pacific Retrovir Retrovir PSM Zincaps Apo-Zopiclone 2011 2011 2011 2011 2011 2012 2011 2011 2013 2011

Trimethoprim Tropisetron Ursodeoxycholic acid Vancomycin hydrochloride Zidovudine [AZT] Zinc and castor oil Zinc sulphate Zopiclone September changes in bold

2011 2012 2011 2011 2013 2011 2011 2011

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 September 2010

29 33 36 41 45 55 85 INSULIN GLULISINE ▲ Inj 100 u per ml, 3 ml .............................................................. 46.07 MUCILAGINOUS LAXATIVES – Only on a prescription ❋ Dry ........................................................................................... 6.02 VITAMIN B COMPLEX ❋ Tab, strong, BPC ...................................................................... 4.70 CLOPIDOGREL Tab 75 mg ............................................................................. 16.25 SODIUM BICARBONATE Cap 840 mg .............................................................................. 8.52 FUROSEMIDE ❋ Inj 10 mg per ml, 2 ml – Up to 5 inj available on a PSO .............. 1.30 5 500 g OP 500 90 100 5 ✔ Apidra ✔ Konsyl-D ✔ B-PlexADE ✔ Apo-Clopidogrel ✔ Sodibic ✔ Frusemide-Claris

CEFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of confirmed ciprofloxacin-resistant gonorrhoea, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly. Inj 500 mg ................................................................................ 2.70 1 ✔ Veracol CEPHALEXIN MONOHYDRATE Cap 500 mg .............................................................................. 8.90 20 ✔ Cephalexin ABM

85 102

MELOXICAM – Special Authority see SA1034 – Retail pharmacy Tab 7.5 mg ............................................................................. 11.50 30 ✔ Arrow-Meloxicam ➽ SA1034 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and 2 The patient has haemophilic arthropathy; and 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated. TENOXICAM ❋ Inj 20 mg .................................................................................. 9.95 1 ✔ AFT

102 109

ZOLEDRONIC ACID – Special Authority see SA1035 – Retail pharmacy Soln for infusion 5 mg in 100 ml ............................................ 600.00 100 ml ✔ Aclasta ➽ SA1035 Special Authority for Subsidy Initial application – (Paget’s disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Paget’s disease; and 2 Any of the following: continued... ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New listings - effective 1 September 2010 (continued)

continued... 2.1 Bone or articular pain; or 2.2 Bone deformity; or 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications; or 2.5 Preparation for orthopaedic surgery; and 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Initial application – (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Any of the following: 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or 1.4 Documented T-Score ≤ -3.0 (see Note); or 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause – Osteoporosis); and 2 The patient will not be prescribed more than one infusion in a 12-month period. Initial application – (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and 2 Any of the following: 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause – glucocorticosteroid therapy); and 3 The patient will not be prescribed more than one infusion in the 12-month approval period. Renewal – (Paget’s disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 Any of the following: 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or 1.2 The patient’s serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or 1.3 Symptomatic disease (prescriber determined); and 2 The patient will not be prescribed more than one infusion in the 12-month approval period. The patient may not have had a prior approval for Paget’s disease within the last 12 months. Renewal – (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents); and 2 The patient will not be prescribed more than one infusion in the 12-month approval period. continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New listings - effective 1 September 2010 (continued)

continued... The patient may not have had a prior approval for 'Underlying cause glucocorticosteroid therapy' within the last 12 months. Renewal – (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause – osteoporosis’ criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Any of the following: 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented BMD ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or 1.4 Documented T-Score ≤ -3.0 (see Note); or 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause – Osteoporosis’ criteria); and 2 The patient will not be prescribed more than one infusion in a 12-month period. Notes: a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable. b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5, and therefore do not require BMD measurement for treatment with bisphosphonates. c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that has quantified this as forces equivalent to a fall from a standing height or less. d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. 111 LIGNOCAINE HYDROCHLORIDE Inj 2%, 5 ml – Up to 5 inj available on a PSO ............................ 23.00 Inj 2%, 20 ml – Up to 5 inj available on a PSO .......................... 15.00 Viscous solution 2% ................................................................ 55.00 CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml ............................................................. 14.95 FLUOROURACIL SODIUM Inj 1 mg for ECP – PCT only – Specialist .................................... 0.77 MESNA – PCT only – Specialist Inj 1 mg for ECP ........................................................................ 2.29 SODIUM CROMOGLYCATE Eye drops 2% ............................................................................ 1.18 50 5 200 ml 5 100 mg 100 mg 5 ml OP ✔ Xylocaine ✔ Xylocaine ✔ Xylocaine Viscous ✔ Nausicalm ✔ Baxter ✔ Baxter ✔ Rexacrom

121 141 145 163

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 September 2010

29 ACARBOSE – Special Authority see SA0925 on the next page – Retail pharmacy ❋ Tab 50 mg ............................................................................. 16.50 90 ✔ Glucobay ❋ Tab 100 mg ........................................................................... 26.70 90 ✔ Glucobay ➽ SA0925 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has type 2 diabetes; and 2 Either: 2.1 Metformin is not tolerated, or is contraindicated; or 2.2 The patient has not responded to the maximum appropriate dose of metformin. PIOGLITAZONE – Special Authority see SA0959 below – Retail pharmacy Tab 15 mg ............................................................................... 2.61 28 ✔ Pizaccord Tab 30 mg ............................................................................... 5.23 28 ✔ Pizaccord Tab 45 mg ............................................................................... 7.80 28 ✔ Pizaccord ➽ SA0959 Special Authority for Subsidy Initial application — (Patients with type 2 diabetes) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient has not achieved glycaemic control on maximum doses of metformin and/or a sulphonylurea or where either or both are contraindicated or not tolerated; or 2 Patient is on insulin. MULTIVITAMINS – Special Authority see SA1036 0963 – Retail pharmacy Powder .................................................................................. 72.00 200 g OP ✔ Paediatric Seravit ➽ SA1036 0963 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: where the patient has inborn errors of metabolism. Either: 1 The patient has inborn errors of metabolism; or 2 For use as a supplement to a ketogenic diet in patients diagnosed with epilepsy. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where patient has had a previous approval for multivitamins. Note: Use of Paediatric Seravit is not recommended as a supplement to a ketogenic diet. CLOPIDOGREL – Special Authority see SA0867 below – Retail pharmacy Tab 75 mg ............................................................................. 16.25 90 ✔ Apo-Clopidogrel 5.05 28 ✔ Apo-Clopidogrel 25.00 28 ✔ Arrow-Clopidogrel (73.38) Plavix ➽ SA0867 Special Authority for Subsidy Initial application — (aspirin allergic patients) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient is allergic to aspirin (see definition below); and 2 Any of the following: The patient has: 2.1 suffered from a stroke, or transient ischaemic attack; or 2.2 experienced an acute myocardial infarction; or continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2010 (continued)

continued... 2.3 experienced an episode of pain at rest of greater than 20 minutes duration due to coronary disease that required admission to hospital for at least 24 hours; or 2.4 had a troponin T or troponin I test result greater than the upper limit of the reference range; or 2.5 had a revascularisation procedure; or 2.6 experienced symptomatic peripheral vascular disease of a severity that has required specialistconsultation. Note: Aspirin allergy is defined as a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates or NSAIDs. Initial application — (aspirin tolerant patients and aspirin naive patients) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Any of the following: The patient has: 1 experienced an acute myocardial infarction; or 2 had an episode of pain at rest of greater than 20 minutes duration due to coronary disease that required admission to hospital for at least 24 hours; or 3 had a troponin T or troponin I test result greater than the upper limit of the reference range; or 4 had a revascularisation procedure. Initial application —(patients awaiting revascularisation) from any relevant practitioner. Approvals valid for 6 months where the patient is on a waiting list or active review list for stenting, coronary artery bypass grafting, or percutaneous coronary angioplasty following acute coronary syndrome. Initial application — (post stenting) from any relevant practitioner. Approvals valid for 6 months where the patient has had a stent inserted in the previous 4 weeks. Initial application — (documented stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has, while on treatment with aspirin or clopidogrel, experienced documented stent thrombosis.. Renewal — (aspirin tolerant patients) from any relevant practitioner. Approvals valid without further renewal unless notified where while on treatment with aspirin the patient has experienced an additional vascular event following the recent cessation of clopidogrel. Renewal — (acute coronary syndrome - aspirin tolerant patients and aspirin naive patients) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Any of the following: The patient has: 1 experienced an acute myocardial infarction; or 2 had an episode of pain at rest of greater than 20 minutes duration due to coronary disease that required admission to hospital for at least 24 hours; or 3 had a troponin T or troponin I test result greater than the upper limit of the reference range; or 4 had a revascularisation procedure. Renewal — (patients awaiting revascularisation) from any relevant practitioner. Approvals valid for 6 months where the patient is on a waiting list or active review list for stenting, coronary artery bypass grafting or percutaneous coronary angioplasty following acute coronary syndrome. Renewal —(post stenting) from any relevant practitioner. Approvals valid for 6 months where the patient has had a stent inserted in the previous 4 weeks. Renewal —(documented stent thrombosis) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has, while on treatment with aspirin or clopidogrel, experienced documented stent thrombosis.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2010 (continued)

46 ATORVASTATIN – Additional subsidy by Special Authority see SA0788 – Retail pharmacy See prescribing guideline ❋ Tab 10 mg ............................................................................. 18.32 30 ✔ Lipitor ❋ Tab 20 mg ............................................................................. 26.70 30 ✔ Lipitor ❋ Tab 40 mg ............................................................................. 37.02 30 ✔ Lipitor ❋ Tab 80 mg ........................................................................... 110.50 30 ✔ Lipitor ➽ SA0788 Special Authority for Manufacturers Price Initial application only from a relevant specialist or general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and 2 Either: 2.1 Patient has severe documented intolerance to simvastatin (blood tests are not required); or 2.2 Both: 2.2.1 Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months; and 2.2.2 Either: 2.2.2.1 All of the following: 2.2.2.1.1 Patient has venous CABG; and 2.2.2.1.2 LDL cholesterol test 1 ≥ 2.0 mmol/litre; and 2.2.2.1.3 LDL cholesterol test 2 ≥ 2.0 mmol/litre (at least 1 week after test 1); or 2.2.2.2 All of the following: 2.2.2.2.1 Patient does not have venous CABG; and 2.2.2.2.2 LDL cholesterol test 1 ≥ 2.5 mmol/litre; and 2.2.2.2.3 LDL cholesterol test 2 ≥ 2.5 mmol/litre (at least 1 week after test 1). Notes: To confirm that cholesterol levels are not still improving, two lipid tests must be carried out during treatment with simvastatin 80 mg, and have results for LDL cholesterol that have reduced by <10% in the second test. The tests must be carried out while the patient is in a fasted state (with the exception of patients with IDDM). The following indications of intolerance to simvastatin, are known as class effects for all statins, and hence are likely to mean that the patient may also be intolerant of atorvastatin: • Constipation, flatulence (may occur in >1% of patients) • Asthenia, abdominal pain, headache (may occur in >1% of patients) • Myopathy, rhabdomyolysis (may occur in <3% of patients) • Elevated serum transaminase levels (may occur in <1% of patients) Statins have been shown to be generally well tolerated in clinical studies, with the rate of discontinuation due to adverse reactions being less than 5%, and similar to the discontinuation rate for patients taking a placebo. AMILORIDE WITH HYDROCHLOROTHIAZIDE ❋ Tab 5 mg with hydrochlorothiazide 50 mg ................................. 5.00 59 50 ✔ Moduretic S29

ISOTRETINOIN – Special Authority see SA0955 – Retail pharmacy Cap 10 mg ............................................................................. 48.48 180 ✔ Oratane Cap 20 mg ............................................................................. 69.70 180 ✔ Oratane ➽ SA0955 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has had an adequate trial on other available treatments and has failed received an inadequate response from these treatments or these are contraindicated; and 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2010 (continued)

continued... 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and 4 Either: 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or 4.2 Patient is male. Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body. Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 Patient has had an adequate trial on other available treatments and has failed received an inadequate response from these treatments or these are contraindicated; and 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and 4 Either: 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or 4.2 Patient is male. Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body. 64 TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription b) a) Only if prescribed for a patient identified with Methicillin-resistant Staphylococcus aureus (MRSA) prior to elective surgery in hospital and the prescription is endorsed accordingly; or b) Only if prescribed for a patient with recurrent Staphylococcus aureus infection and the prescription is endorsed accordingly Soln 1% ................................................................................... 5.90 500 ml OP ✔ healthE MALATHION Liq 0.5% ................................................................................... 3.79 200 ml OP ✔ A-Lices

66 86

AZITHROMYCIN – Subsidy by endorsement; can be waived by Special Authority see SA0964 a) Maximum of 2 tab per prescription; can be waived by Special Authority see SA0964 b) Up to 8 4 tab available on a PSO c) Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to Chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly; can be waived by Special Authority see SA0964. Tab 500 mg ............................................................................. 5.95 2 OP ✔ Arrow-Azithromycin ETHAMBUTOL HYDROCHLORIDE – No patient co-payment payable Tab 100 mg ........................................................................... 48.01 Tab 400 mg ........................................................................... 49.34 56 56 ✔ Myambutol S29 ✔ Myambutol S29

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2010 (continued)

97 INTERFERON ALPHA-2A – PCT – Retail pharmacy-Specialist a) See prescribing guideline b) Only one multidose cartridge starter pack to be prescribed and dispensed per patient. Inj 3 m iu prefilled syringe ....................................................... 31.32 1 ✔ Roferon-A Inj 6 m iu prefilled syringe ....................................................... 62.64 1 ✔ Roferon-A Inj 9 m iu prefilled syringe ....................................................... 93.96 1 ✔ Roferon-A ANTI-INFLAMMATORY NON STEROIDAL DRUGS (NSAIDS) ➽ SA1038 0291 Special Authority for Manufacturers Price Notes: Subsidy for patients with existing approvals prior to 1 September 2010. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 September 2010. Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Inflammatory arthritis (including osteoarthritis with an inflammatory component); and 2 Stabilised and are well controlled on the particular NSAID medication. Renewal from any medical practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. ALENDRONATE SODIUM – Special Authority see SA1039 0990 – Retail pharmacy Tab 70 mg ............................................................................. 35.91 4 ✔ Fosamax

101

108

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA1039 0990 – Retail pharmacy Tab 70 mg with cholecalciferol 5,600 iu .................................. 35.91 4 ✔ Fosamax Plus ➽ SA1039 0990 Special Authority for Subsidy Initial application – (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0 (see Note); or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Dubbo Garvan) which incorporates BMD measurements (see Note); or 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause – Osteoporosis). Initial application – (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and 2 Either Any of the following: 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause – glucocorticosteroid therapy). Renewal – (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2010 (continued)

continued... Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents). Renewal – (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause – osteoporosis’ criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented BMD ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0 (see Note); or 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Dubbo Garvan) which incorporates BMD measurements (see Note); or 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause – Osteoporosis’ criteria). Notes: a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable. b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5, and therefore do not require BMD measurement for treatment with bisphosphonates. c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less. d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. 111 LIGNOCAINE Gel 2%, 10 ml urethral syringe – Up to 5 each available on a PSO .................................... 43.26

✔ Pfizer

111

LIGNOCAINE HYDROCHLORIDE Inj 0.5%, 5 ml – Up to 5 inj available on a PSO ......................... 44.10 50 ✔ Xylocaine Only if prescribed on prescription for a dialysis patient or child with rheumatic fever or on a PSO for emergency use. Inj 1%, 5 ml – Up to 5 inj available on a PSO ............................ 35.00 50 ✔ Xylocaine Only if prescribed on prescription for a dialysis patient or child with rheumatic fever or on a PSO for emergency use. Inj 1%, 20 ml – Up to 5 inj available on a PSO .......................... 20.00 5 ✔ Xylocaine Only if prescribed on prescription for a dialysis patient or child with rheumatic fever or on a PSO for emergency use. LIGNOCAINE WITH CHLORHEXIDINE Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Up to 5 each available on a PSO ..................................... 43.26

111

✔ Pfizer

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2010 (continued)

122 ONDANSETRON – Retail pharmacy-Specialist a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 c) Not more than one prescription per month; can be waived by Special Authority see SA0887. d) The maximum of 6 tab per dispensing cannot be waived via Access Exemption Criteria. Tab 4 mg ............................................................................... 17.18 10 ✔ Zofran Tab disp 4 mg ........................................................................ 17.18 10 ✔ Zofran Zydis Tab 8 mg ............................................................................... 33.89 20 ✔ Zofran Tab disp 8 mg ........................................................................ 20.43 10 ✔ Zofran Zydis TROPISETRON – Retail pharmacy-Specialist a) Maximum of 6 cap per prescription b) Maximum of 3 cap per dispensing c) Not more than one prescription per month. Cap 5 mg ............................................................................... 77.41 ALPRAZOLAM – Month Restriction Tab 250 µg .............................................................................. 3.15 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 500 µg .............................................................................. 4.10 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 1 mg ................................................................................. 7.25 ‡ Safety cap for extemporaneously compounded oral liquid preparations.

122

5 50 50 50

✔ Navoban ✔ Arrow-Alprazolam ✔ Arrow-Alprazolam ✔ Arrow-Alprazolam

129

BUSPIRONE HYDROCHLORIDE – Special Authority see SA0863 – Retail pharmacy Month Restriction Tab 5 mg ............................................................................... 28.00 100 Tab 10 mg ............................................................................. 17.00 100 DIAZEPAM Tab 2 mg – Month Restriction.................................................. 11.44 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 5 mg – Month Restriction.................................................. 13.71 ‡ Safety cap for extemporaneously compounded oral liquid preparations. LORAZEPAM – Month Restriction Tab 1 mg ............................................................................... 16.42 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 2.5 mg ............................................................................ 11.17 ‡ Safety cap for extemporaneously compounded oral liquid preparations. OXAZEPAM – Month Restriction Tab 10 mg ............................................................................... 1.98 (5.89) ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 15 mg ............................................................................... 2.45 (8.13) ‡ Safety cap for extemporaneously compounded oral liquid preparations. 500 500

✔ Pacific Buspirone ✔ Pacific Buspirone ✔ Arrow-Diazepam ✔ Arrow-Diazepam

130

250 100

✔ Ativan ✔ Ativan

130

100 Ox-Pam 100 Ox-Pam

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2010 (continued)

132 LORMETAZEPAM – Month Restriction Tab 1 mg ................................................................................. 3.11 (23.50) ‡ Safety cap for extemporaneously compounded oral liquid preparations. MIDAZOLAM Tab 7.5 mg – Month Restriction............................................... 10.38 (25.00) ‡ Safety cap for extemporaneously compounded oral liquid preparations. NITRAZEPAM – Month Restriction Tab 5 mg ................................................................................. 2.00 (4.98) ‡ Safety cap for extemporaneously compounded oral liquid preparations. TEMAZEPAM – Month Restriction Tab 10 mg ............................................................................... 0.83 ‡ Safety cap for extemporaneously compounded oral liquid preparations. TRIAZOLAM – Month Restriction Tab 125 µg .............................................................................. 5.10 (6.50) ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 250 µg .............................................................................. 4.10 (7.20) ‡ Safety cap for extemporaneously compounded oral liquid preparations. ZOPICLONE – Month Restriction Tab 7.5 mg ............................................................................ 21.02 30 Noctamid

132

100 Hypnovel

132

100 Nitrados

132

✔ Normison

132

100 Hypam 100 Hypam

132 140

500

✔ Apo-Zopiclone

CAPECITABINE – Retail pharmacy-Specialist – Special Authority see SA1040 0869 Tab 150 mg ......................................................................... 115.00 60 ✔ Xeloda Tab 500 mg ......................................................................... 705.00 120 ✔ Xeloda ➽ SA1040 0869 Special Authority for Subsidy Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following: 1 The patient has advanced gastrointestinal malignancy; or 2 The patient has metastatic breast cancer*; or 3 The patient has stage III (Duke’s stage C) colorectal*# cancer and undergone surgery; or 4 Both: 4.1 The patient has poor venous access or needle phobia*; and 4.2 The patient requires a substitute for single agent fluoropyrimidine*. Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 The patient requires continued therapy; or 2 The tumour has relapsed and requires re-treatment. Note: Indications marked with * are Unapproved Indications, # capecitabine is approved for stage III (Duke’s stage C) colon cancer.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 September 2010

35 CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE ( price) ❋ Adhesive gel 8.7% with cetalkonium chloride 0.01% ................. 2.06 (5.62) CLOPIDOGREL ( subsidy) Tab 75 mg ............................................................................... 5.05 SODIUM CHLORIDE ( subsidy) Inj 23.4%, 20 ml ..................................................................... 31.25 ATORVASTATIN ( subsidy) See prescribing guideline ❋ Tab 10 mg ............................................................................. 18.32 ❋ Tab 20 mg ............................................................................. 26.70 ❋ Tab 40 mg ............................................................................. 37.02 ❋ Tab 80 mg ........................................................................... 110.50 CAPTOPRIL ( subsidy) ❋‡ Oral liq 5 mg per ml .............................................................. 94.99 Oral liquid restricted to children under 12 years of age. AMILORIDE WITH HYDROCHLOROTHIAZIDE ( subsidy) ❋ Tab 5 mg with hydrochlorothiazide 50 mg ................................. 5.00 15 g OP Bonjela 28 5 ✔ Apo-Clopidogrel ✔ Biomed

41 44 46

30 30 30 30 95 ml OP

✔ Lipitor ✔ Lipitor ✔ Lipitor ✔ Lipitor ✔ Capoten

56 67

✔ Moduretic

COAL TAR ( subsidy) Soln BP – Only in combination ................................................ 12.95 200 ml ✔ David Craig Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteriod – Plain With or without other dermatological galenicals. SODIUM CITRO-TARTRATE ( subsidy) ❋ Grans eff 4 g sachets ............................................................... 2.71 HYDROCORTISONE ( subsidy) ❋ Inj 50 mg per ml, 2 ml .............................................................. 3.99 a) Up to 5 inj available on a PSO b) Only on a PSO PHENOXYMETHYLPENICILLIN (PENICILLIN V) ( subsidy) Cap potassium salt 250 mg – Up to 30 cap available on a PSO ................................................................. 9.71 Cap potassium salt 500 mg .................................................... 11.70 28 1 ✔ Ural ✔ Solu-Cortef

75 77

50 50

✔ Cilicaine VK ✔ Cilicaine VK

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 September 2010 (continued)

89 NYSTATIN ( subsidy) Tab 500,000 u ....................................................................... 14.16 Cap 500,000 u ....................................................................... 12.81 50 50 ✔ Nilstat ✔ Nilstat ✔ Myambutol ✔ Myambutol ✔ Brufen Retard ✔ Xylocaine ✔ Xylocaine

ETHAMBUTOL HYDROCHLORIDE – No patient co-payment payable ( subsidy) Tab 100 mg ........................................................................... 48.01 56 Tab 400 mg ........................................................................... 49.34 56 IBUPROFEN ( subsidy) ❋ Tab long-acting 800 mg ........................................................... 9.12 LIGNOCAINE HYDROCHLORIDE ( subsidy) Inj 1%, 5 ml – Up to 5 inj available on a PSO ............................ 35.00 Inj 1%, 20 ml – Up to 5 inj available on a PSO .......................... 20.00 30 50 5

101 111

111

LIGNOCAINE WITH PRILOCAINE – Special Authority see SA0906 – Retail pharmacy ( subsidy) Crm 2.5% with prilocaine 2.5% ............................................... 45.00 30 g OP ✔ EMLA Crm 2.5% with prilocaine 2.5% (5 g tubes) ............................. 45.00 5 ✔ EMLA MORPHINE SULPHATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Cap long-acting 10 mg ............................................................. 2.22 Cap long-acting 30 mg ............................................................. 3.20 Cap long-acting 100 mg ........................................................... 8.05 MORPHINE SULPHATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Cap long-acting 60 mg ............................................................. 6.90 MORPHINE TARTRATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Inj 80 mg per ml, 1.5 ml ......................................................... 30.00 Inj 80 mg per ml, 5 ml ............................................................ 75.00

113

10 10 10

✔ m-Eslon ✔ m-Eslon ✔m-Eslon

113

✔ m-Eslon

113

5 5

✔ Hospira ✔ Hospira

118

GABAPENTIN (NEURONTIN) – Special Authority see SA0973 – Retail pharmacy ( subsidy) ▲ Tab 600 mg ........................................................................... 67.50 100 ✔ Neurontin ▲ Cap 100 mg ........................................................................... 13.26 100 ✔ Neurontin ▲ Cap 300 mg ........................................................................... 39.76 100 ✔ Neurontin ▲ Cap 400 mg ........................................................................... 53.01 100 ✔ Neurontin HALOPERIDOL ( subsidy) Tab 500 µg – Up to 30 tab available on a PSO ........................... 5.42 Tab 1.5 mg – Up to 30 tab available on a PSO ........................... 8.20 Tab 5 mg – Up to 30 tab available on a PSO ............................ 25.84 Oral liq 2 mg per ml – Up to 200 ml available on a PSO ............ 19.87 Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 18.74 100 100 100 100 ml 10 ✔ Serenace ✔ Serenace ✔ Serenace ✔ Serenace ✔ Serenace

125

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 September 2010 (continued)

141 141 FLUOROURACIL SODIUM ( subsidy) Inj 50 mg per ml, 10 ml – PCT only – Specialist ....................... 26.25 FLUOROURACIL SODIUM ( subsidy) Inj 50 mg per ml, 20 ml – PCT only – Specialist ......................... 7.50 Inj 50 mg per ml, 50 ml – PCT only – Specialist ....................... 18.00 Inj 50 mg per ml, 100 ml – PCT only – Specialist ..................... 34.50 METHOTREXATE ( subsidy) ❋ Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ..... 48.00 ❋ Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist ... 90.00 ❋ Inj 1 mg for ECP – PCT only – Specialist ................................... 0.10 DACARBAZINE – PCT only – Specialist ( subsidy) Inj 200 mg ............................................................................. 48.00 Inj 200 mg for ECP ................................................................. 48.00 MESNA – PCT only – Specialist ( subsidy) Tab 400 mg ......................................................................... 210.65 Tab 600 mg ......................................................................... 314.40 Inj 100 mg per ml, 4 ml ........................................................ 137.04 Inj 100 mg per ml, 10 ml ...................................................... 314.66 FLUTAMIDE – Retail pharmacy-Specialist ( subsidy) Tab 250 mg ........................................................................... 55.00 NEDOCROMIL ( subsidy) Aerosol inhaler, 2 mg per dose CFC-free ................................. 28.07 SODIUM CROMOGLYCATE ( subsidy) Powder for inhalation, 20 mg per dose .................................... 17.94 Aerosol inhaler, 5 mg per dose CFC-free ................................. 28.07 THEOPHYLLINE ( subsidy) ❋‡ Oral liq 80 mg per 15 ml ....................................................... 15.50 GLYCEROL ( subsidy) ❋ Liquid – Only in combination ................................................... 17.86 (19.80) (24.75) 0.89 (3.00) 1.79 (4.90) 4.47 (10.00) Only in extemporaneously compounded oral liquid preparations. 5 1 1 1 5 1 1 mg ✔ Fluorouracil Ebewe ✔ Fluorouracil Ebewe ✔ Fluorouracil Ebewe ✔ Fluorouracil Ebewe ✔ Hospira ✔ Hospira ✔ Baxter

142

143

1 ✔ Hospira 200 mg OP ✔ Baxter 50 50 15 15 100 ✔ Uromitexan ✔ Uromitexan ✔ Uromitexan ✔ Uromitexan ✔ Flutamin

145

149 160 160

112 dose OP ✔ Tilade 50 dose ✔ Intal Spincaps 112 dose OP ✔ Vicrom 500 ml 2,000 ml ABM MidWest 100 ml PSM 200 ml PSM 500 ml PSM ✔ Nuelin

160 171

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 September 2010

15 “Month restriction” means that no Subsidy is available: a) unless the Community Pharmaceutical is dispensed on the Prescription of a Practitioner; and b) for any quantity of that Community Pharmaceutical dispensed on the Prescription (whether or not dispensed as a repeat) in excess of a Monthly Lot.

Changes to Brand Name

Effective 1 September 2010

113 MORPHINE TARTRATE a) Only on a controlled drug form b) No patient co-payment payable Inj 80 mg per ml, 1.5 ml ......................................................... 30.00 Inj 80 mg per ml, 5 ml ............................................................ 75.00 METHOTREXATE ❋ Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist ..... 48.00 ❋ Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist ... 90.00 DACARBAZINE – PCT only – Specialist Inj 200 mg ............................................................................. 48.00

5 5 5 1 1

✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne ✔ Hospira Mayne

142

143

Changes to Section E Part I

Effective 1 September 2010

193 AZITHROMYCIN ✔ Tab 500 mg – Subsidy by endorsement – See note on page 86 ........................................................... 8 4 LIGNOCAINE ✔ Gel 2%, 10 ml urethral syringe.................................................5 LIGNOCAINE WITH CHLORHEXIDINE ✔ Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes ..................................................................5

195 195

Changes to Sole Subsidised Supply

Effective 1 September 2010

For the list of new Sole Subsidised Supply products effective 1 September 2010 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 14-20.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 September 2010

30 COPPER ❋ Tab, diagnostic – Not on a BSO ................................................. 5.02 (31.80) GLUCOSE OXIDASE Urine diagnostic test – Not on a BSO ......................................... 4.11 (7.00) Urine diagnostic test with peroxidase – Not on a BSO ................. 4.11 (6.26) 4.13 (8.65) DOCUSATE SODIUM – Only on a prescription ❋ Tab 50 mg ................................................................................ 3.95 (4.89) ❋ Tab 120 mg .............................................................................. 5.49 (6.73) MULTIVITAMINS – Special Authority see SA0963 – Retail pharmacy Tab ......................................................................................... 19.65 Oral liq .................................................................................... 13.50 ATORVASTATIN ❋ Tab 10 mg ............................................................................... 1.77 ❋ Tab 20 mg ............................................................................... 2.60 ❋ Tab 40 mg ............................................................................... 4.38 ❋ Tab 80 mg ............................................................................... 7.73 BUSERELIN ACETATE Inj 1 mg per ml, 5.5 ml .......................................................... 195.00 (272.53) AMOXYCILLIN Grans for oral liq 125 mg per 5 ml – Up to 200 ml available on a PSO ................................................................. 1.00 36 OP Clinitest 50 strip OP Diabur 5000 50 strip OP Diastix Clinistix 100 Coloxyl 100 Coloxyl 100 ✔ Ketovite 150 ml OP ✔ Ketovite Liquid 30 30 30 30 2 Suprefact ✔ Lorstat 10 ✔ Lorstat 20 ✔ Lorstat 40 ✔ Lorstat 80

100 ml

✔ Ranbaxy Amoxicillin

109 111

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – Special Authority see SA1039 – Retail pharmacy Tab 70 mg with cholecalciferol 2,800 iu................................... 35.91 4 ✔ Fosamax Plus BUPIVACAINE HYDROCHLORIDE Inj 0.5%, 4 ml ......................................................................... 29.35 Inj 0.5%, 8% glucose, 4 ml ..................................................... 24.50 5 5 ✔ Marcain Isobaric ✔ Marcain Heavy

141

FLUOROURACIL SODIUM Inj 1 mg for ECP – PCT only – Specialist ................................... 0.01 1 mg ✔ Baxter Note – This product has been replaced with a 100 mg pack size listed 1 September 2010. MESNA – PCT only – Specialist Inj 1 mg for ECP ....................................................................... 0.02 1 mg ✔ Baxter Note – This product has been replaced with a 100 mg pack size listed 1 September 2010.

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

145

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 September 2010 (continued)

155 166 CYPROHEPTADINE HYDROCHLORIDE ❋ Tab 4 mg ................................................................................. 6.27 PHENYLEPHRINE HYDROCHLORIDE WITH ZINC SULPHATE ❋ Eye drops 0.12% with zinc sulphate 0.25% ................................ 4.51 100 15 ml OP ✔ Periactin ✔ Zincfrin

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 November 2010

119 LEVETIRACETAM – Special Authority see SA0921 – Retail pharmacy Tab ..................................................................................... CBS 60 ✔ Keppra

Effective 1 December 2010

67 COAL TAR Soln BP – Only in combination ................................................ 32.37 500 ml ✔ PSM 12.95 200 ml ✔ David Craig Up to 10 % Only in combination with a dermatological base or proprietary Topical Corticosteriod – Plain With or without other dermatological galenicals. FLUOXETINE HYDROCHLORIDE ❋ Cap 20 mg ............................................................................... 2.89 Note – Fluox cap 20 mg 84 cap pack remains listed. GLYCEROL ❋ Liquid – Only in combination ................................................... 17.86 (19.80) (24.75) 0.89 (3.00) 1.79 (4.90) 4.47 (10.00) Only in extemporaneously compounded oral liquid preparations. 90 ✔ Fluox

116

171

2,000 ml 100 ml

✔ PSM ABM MidWest PSM

200 ml PSM 500 ml PSM

Effective 1 March 2011

63 74 121 HYDROCORTISONE BUTYRATE WITH CHLORQUINALDOL – Only on a prescription Crm 0.1% with chlorquinaldol 3% ............................................. 3.49 15 g OP METHYLERGOMETRINE Inj 200 µg per ml, 1 ml – Up to 10 inj available on a PSO ........... 9.28 CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml ............................................................. 14.95 10 5 ✔ Locoid C ✔ Hospira S29 ✔ Valoid (AFT)

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 September 2010

18 ATORVASTATIN Tab 10 mg .............................................................................. 18.32 30 Tab 20 mg .............................................................................. 26.70 30 Tab 40 mg .............................................................................. 37.02 30 Tab 80 mg ............................................................................ 110.50 30 Note – Lorstat tab 10 mg, 20 mg, 40 mg and 80 mg to be delisted 1 September 2010. BARIUM SULPHATE Oral suspension 2.2%, 250 ml ............................................... 175.00 Oral suspension 2.2%, 450 ml ............................................... 220.00 CALCIUM GLUCONATE Gel, 2.5%, 50 g ..................................................................... 420.00 CAPTOPRIL Oral liq 5 mg per ml ................................................................. 94.99 24 24 20 95 ml Lipitor Lipitor Lipitor Lipitor

CT Plus+ CT Plus+ healthE Capoten Veracol Veracol

21 21 22

CEFTRIAXONE SODIUM Inj 500 mg – 1% DV Nov-10 to 2013 ........................................ 2.70 1 Inf 2 g – 1% DV Nov-10 to 2013 ............................................... 5.20 1 Note – AFT ceftriaxone sodium inj 500 mg and inf 2 g to be delisted 1 November 2010. CEPHALEXIN MONOHYDRATE Cap 500 mg ............................................................................. 8.90 CETOMACROGOL Crm BP, 100 g ........................................................................ 33.00 CHLORHEXIDINE Foaming liquid 4%, 50 ml ........................................................ 37.20 CHLORHEXIDINE IN ALCOHOL Soln 0.5% with 70% alcohol, 25 ml (tinted pink) .................... 232.50 20 20 20 150

22 23 23 23 24

Cephalexin ABM healthE healthE healthE

CLOPIDOGREL Tab 75 mg – 1% DV Nov-10 to 2013 ...................................... 16.25 90 Apo-Clopidogrel Note – Arrow-Clopidogrel, Plavix and Apo-Clopidogrel 28 tab packs to be delisted 1 November 2010. CYCLIZINE LACTATE (brand name change) Inj 50 mg per ml, 1 ml ............................................................. 14.95 Note – Valoid (AFT) to be delisted 1 November 2010. DACARBAZINE ( price, brand name change and addition of HSS) Inj 200 mg – 1% DV Nov-10 to 2013 ...................................... 48.00 ETHAMBUTOL HYDROCHLORIDE ( price) Tab 100 mg ............................................................................ 48.01 Tab 400 mg ............................................................................ 49.34 5 Nausicalm

26 29

1 56 56

Mayne Hospira Myambutol Myambutol

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 September 2010 (continued)

31 FLUOROURACIL SODIUM (Addition of HSS) Inj 50 mg per ml, 10 ml – 1% DV Nov-10 to 2013 ( price) ..... 26.25 Inj 50 mg per ml, 20 ml – 1% DV Nov-10 to 2013 ( price) ....... 7.50 Inj 50 mg per ml, 50 ml – 1% DV Nov-10 to 2013 ( price) ..... 18.00 Inj 50 mg per ml, 100 ml – 1% DV Nov-10 to 2013 ( price) ... 34.50 FLUTAMIDE ( price and addition of HSS) Tab 250 mg – 1% DV Nov-10 to 2013 .................................... 55.00 5 1 1 1 100 Fluorouracil Ebewe Fluorouracil Ebewe Fluorouracil Ebewe Fluorouracil Ebewe Flutamin Frusemide-Claris

31 32

FUROSEMIDE Inj 10 mg per ml, 2 ml – 1% DV Nov-10 to 2013 ....................... 1.30 5 Note – Mayne furosemide inj 10 mg per ml, 2 ml to be delisted 1 November 2010. HALOPERIDOL ( price and addition of HSS) Tab 500 µg – 1% DV Nov-10 to 2013 ....................................... 5.42 Tab 1.5 mg – 1% DV Nov-10 to 2013 ....................................... 8.20 Tab 5 mg – 1% DV Nov-10 to 2013 ........................................ 25.84 Oral liq 2 mg per ml – 1% DV Nov-10 to 2013 ......................... 19.87 Inj 5 mg per ml, 1 ml – 1% DV Nov-10 to 2013 ....................... 18.74 HYDROCORTISONE Inj 50 mg per ml, 2 ml – 1% DV Nov-10 to 2013 ....................... 3.99 INSULIN GLULISINE Inj 100 iu per ml, 3 ml ............................................................. 46.07 LIGNOCAINE HYDROCHLORIDE ( price and addition of HSS) Pump spray 10%, 50 ml CFC-free – 1% DV Nov-10 to 2013 .... 75.00 100 100 100 100 ml 10 1 5 50 ml

Serenace Serenace Serenace Serenace Serenace Solu-Cortef Apidra Xylocaine

34 35 38 39

LIGNOCAINE HYDROCHLORIDE WITH ADRENALINE ( price and addition of HSS) Inj 1% with 1:100,000 of adrenaline 5 ml – 1% DV Nov-10 to 2013 .................................................... 27.00 10 Inj 1% with 1:200,000 of adrenaline 20 ml – 1% DV Nov-10 to 2013 .................................................... 50.00 5 Inj 2% with 1:200,000 of adrenaline 20 ml – 1% DV Nov-10 to 2013 .................................................... 60.00 5 LIGNOCAINE WITH PRILOCAINE ( price and addition of HSS) Crm 2.5% with prilocaine 2.5%, 30 g – 1% DV 1 Nov-10 to 2013 ................................................. 45.00 Patch 2.5% with prilocaine 2.5% – 1% DV 1 Nov-10 to 2013 ............................................... 115.00 Crm 2.5% with prilocaine 2.5%, 5 g – 1% DV 1 Nov-10 to 2013 ................................................. 45.00 MESNA ( price and addition of HSS) Tab 400 mg – 1% DV 1 Nov-10 to 2013 ............................... 210.65 Tab 600 mg – 1% DV 1 Nov-10 to 2013 ............................... 314.40 Inj 100 mg per ml, 4 ml – 1% DV 1 Nov-10 to 2013 .............. 137.04 Inj 100 mg per ml, 10 ml – 1% DV 1 Nov-10 to 2013 ............ 314.66

Xylocaine Xylocaine Xylocaine

30 g 20 5 50 50 15 15

EMLA EMLA EMLA Uromitexan Uromitexan Uromitexan Uromitexan

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 September 2010 (continued)

40 METHOTREXATE Inj 25 mg per ml, 2 ml – 1% DV Nov-10 to 2013 ..................... 48.00 Inj 25 mg per ml, 20 ml – 1% DV Nov-10 to 2013 ................... 90.00 MITOMYCIN C Inj 5 mg .................................................................................. 72.75 MORPHINE SULPHATE (Addition of HSS) Cap long-acting 10 mg – 1% DV Nov-10 to 2013 ( price) ........ 2.22 Cap long-acting 30 mg – 1% DV Nov-10 to 2013 ( price) ........ 3.20 Cap long-acting 60 mg – 1% DV Nov-10 to 2013 ( price) ........ 6.90 Cap long-acting 100 mg – 1% DV Nov-10 to 2013 ( price) ...... 8.05 MORPHINE TARTRATE ( price, amended brand name and addition of HSS) Inj 80 mg per ml, 1.5 ml – 1% DV Nov-10 to 2013 .................. 30.00 Inj 80 mg per ml, 5 ml– 1% DV Nov-10 to 2013 ...................... 75.00 MUCILAGINOUS LAXATIVES Dry – 1% DV Nov-10 to 2013.................................................... 6.02 Note – Konsyl-D 325g pack to be delisted 1 November 2010 NYSTATIN ( price and addition of HSS) Tab 500,000 u – 1% DV Nov-10 to 2013 ................................ 14.16 Cap 500,000 u – 1% DV Nov-10 to 2013 ................................ 12.81 OIL IN WATER EMULSION Crm 100 g............................................................................... 32.00 PHENOXYMETHYLPENICILLIN (PENICILLIN V) ( price and addition of HSS) Cap potassium salt 250 mg – 1% DV Nov-10 to 2013 ............... 9.71 Cap potassium salt 500 mg – 1% DV Nov-10 to 2013 ............. 11.70 PHENTOLAMINE MESYLATE ( price) Inj 10 mg per ml, 1 ml ............................................................ 31.65 PRILOCAINE HYDROCHLORIDE ( price and addition of HSS) Inj 0.5%, 50 ml – 1% DV Nov-10 to 2013 .............................. 100.00 Inj 2%, 5 ml – 1% DV Nov-10 to 2013 ..................................... 55.00 RETINOL PALMITATE Oint 50 g ................................................................................. 57.20 5 1 1 10 10 10 10 5 5 500 g Hospira Hospira Arrow m-Eslon m-Eslon m-Eslon m-Eslon Mayne Hospira Mayne Hospira Konsyl-D

42 43

50 50 20 50 50 5 5 10 20

Nilstat Nilstat healthE Cilicaine VK Cilicaine VK Regitine Citanest Citanest healthE

44 47

47 48

50 51

ROPIVACAINE HYDROCHLORIDE WITH FENTANYL ( price and addition of HSS) Inf 2 mg per ml with 2 µg of fentanyl per ml, 100 ml – 1% DV Nov-10 to 2013 .................................................. 198.50 5 Inf 2 mg per ml with 2 µg of fentanyl per ml, 200 ml – 1% DV Nov-10 to 2013 .................................................. 270.00 5 SODIUM BICARBONATE Cap 840 mg .............................................................................. 8.52 100

Naropin Naropin Sodibic

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 September 2010 (continued)

52 53 53 57 SODIUM CHLORIDE ( price and addition of HSS) Inj 23.4%, 20 ml – 1% DV Nov-10 to 2013 .............................. 31.25 SODIUM DIOTRIZOATE ( price) Powder for oral soln 3.705 g, 10 ml sachet ........................... 156.12 SODIUM FLUORESCEIN Inj 100 mg per ml, 5 ml – 1% DV Nov-10 to 2013 ................. 125.00 SOFT WHITE PARAFFIN WITH PARAFFIN LIQUID Oint 50% with 50% paraffin liquid, 100 g .................................. 62.00 5 50 12 20 Biomed Ioscan Fluorescite healthE

Effective 1 August 2010

18 18 ASCORBIC ACID Tab 100 mg – 1% DV Oct-10 to 2013 ..................................... 13.80 ATORVASTATIN Tab 10 mg – 1 % DV Dec-2010 - 31/7/12................................. 1.77 Tab 20 mg – 1 % DV Dec-2010 - 31/7/12................................. 2.60 Tab 40 mg – 1 % DV Dec-2010 - 31/7/12................................. 4.38 Tab 80 mg – 1 % DV Dec-2010 - 31/7/12................................. 7.73 AZATHIOPRINE Tab 50 mg – 1% DV Oct-10 to 2013 ....................................... 18.45 Inj 50 mg – 1% DV Oct-10 to 2013 ......................................... 60.00 CEFTRIAXONE SODIUM Inj 1 g – 1% DV Oct-10 to 2013 .............................................. 10.49 Note – AFT ceftriaxone sodium inj 1 g to be delisted 1 October 2010 CLOMIPHENE CITRATE Tab 50 mg ............................................................................... 2.50 Note – Phenate tab 50 mg to be delisted 1 October 2010 DANTHRON WITH POLOXAMER Oral liq 75 mg with poloxamer 1 g per 5 ml .............................. 13.95 FUROSEMIDE ( price) Tab 500 mg ........................................................................... 25.00 HYDROCORTISONE WITH CINCHOCAINE Oint 5 mg with cinchocaine hydrochloride 5 mg per g .............. 15.00 Suppos 5 mg with cinchocaine hydrochloride 5 mg per g........... 9.90 INDAPAMIDE Tab 2.5 mg – 1% DV Oct-10 to 2013 ........................................ 2.95 Note – Napamide tab 2.5 mg to be delisted 1 October 2010 500 30 30 30 30 100 1 5 Vitala-C Lorstat 10 Lorstat 20 Lorstat 40 Lorstat 80 Imuprine Imuran Aspen Ceftriaxone

Phenate

26 32 34

300 ml 50 30 g 12 90

Pinorax Forte Urex Forte Proctosedyl Proctosedyl Dapa-Tabs

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 August 2010 (continued)

35 INSULIN GLULISINE Inj 100 iu per ml, 10 ml ........................................................... 27.03 Inj 100 iu per ml, 3 ml disposable pen ..................................... 46.07 1 5 Apidra Apidra SoloStar

IPRATROPIUM BROMIDE Nebuliser soln, 250 µg per ml, 1 ml – 1% DV Oct-10 to 2013 .... 3.79 20 Univent Nebuliser soln, 250 µg per ml, 2 ml – 1% DV Oct-10 to 2013 .... 4.06 20 Univent Note – Ipratropium Steri-Neb nebuliser soln, 250 µg per ml, 1 ml and 2 ml to be delisted 1 October 2010 KETONE BLOOD BETA-KETONE ELECTRODES ( price) Test strips ................................................................................ 7.07 LEVONORGESTREL Subdermal implant (2 x 75 mg rods) ...................................... 133.65 METHADONE HYDROCHLORIDE ( price and addition of HSS) Tab 5 mg – 1% DV Oct-10 to 2013 ........................................... 1.85 QUETIAPINE Tab 25 mg ............................................................................... 7.00 Tab 100 mg ........................................................................... 14.00 Tab 200 mg ........................................................................... 24.00 Tab 300 mg ........................................................................... 40.00 RISPERIDONE Tab 0.5 mg ............................................................................... 3.51 SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1% DV Oct-10 to 2013 ......................... 25.00 Note – Microlex enema to be delisted 1 October 2010 TAMSULOSIN HYDROCHLORIDE Cap 400 µg – 1% DV Oct-10 to 2013........................................ 5.98 10 strip Optium Blood Ketone Test Strips Jadelle Methatabs Dr Reddy’s Quetiapine Dr Reddy’s Quetiapine Dr Reddy’s Quetiapine Dr Reddy’s Quetiapine Dr Reddy’s Risperidone

38 40 49

1 10 60 60 60 60 60

Micolette

Tamsulosin-Rex

Section H changes to Part III

Effective 1 September 2010

LIGNOCAINE Viscous solution 2% For patients with head, neck and oesophageal cancer for up to 9 weeks following radiation therapy.

Effective 1 August 2010

INDOMETHACIN Cap long-acting 75 mg S29 For any indication approved by the hospital service Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Index

Pharmaceuticals and brands A A-Lices .............................................................. 27 Acarbose ........................................................... 24 Aclasta .............................................................. 21 Alendronate sodium ........................................... 28 Alendronate sodium with cholecalciferol ....... 28, 36 Alprazolam ......................................................... 30 Amiloride with hydrochlorothiazide ............... 26, 32 Amoxycillin ........................................................ 36 Anti-inflammatory non steroidal drugs (NSAIDS) ... 28 Apidra .................................................... 21, 40, 43 Apidra SoloStar .................................................. 43 Apo-Clopidogrel ............................... 21, 24, 32, 39 Apo-Zopiclone.................................................... 31 Arrow-Alprazolam .............................................. 30 Arrow-Azithromycin ........................................... 27 Arrow-Clopidogrel .............................................. 24 Arrow-Diazepam ................................................ 30 Arrow-Meloxicam............................................... 21 Ascorbic acid ..................................................... 42 Aspen Ceftriaxone .............................................. 42 Ativan ................................................................ 30 Atorvastatin................................ 26, 32, 36, 39, 42 Azathioprine ....................................................... 42 Azithromycin ................................................ 27, 35 B B-PlexADE ......................................................... 21 Barium sulphate ................................................. 39 Bonjela .............................................................. 32 Brufen Retard ..................................................... 33 Bupivacaine hydrochloride.................................. 36 Buserelin acetate ................................................ 36 Buspirone hydrochloride..................................... 30 C Calcium gluconate ............................................. 39 Capecitabine ...................................................... 31 Capoten ....................................................... 32, 39 Captopril ...................................................... 32, 39 Ceftriaxone sodium ................................ 21, 39, 42 Cephalexin monohydrate .............................. 21, 39 Cephalexin ABM ........................................... 21, 39 Cetomacrogol .................................................... 39 Chlorhexidine ..................................................... 39 Chlorhexidine in alcohol...................................... 39 Choline salicylate with cetalkonium chloride........ 32 Cilicaine VK.................................................. 32, 41 Citanest ............................................................. 41 Clinistix .............................................................. 36 Clinitest.............................................................. 36 Clomiphene citrate ............................................. 42 Clopidogrel ...................................... 21, 24, 32, 39 Coal tar ........................................................ 32, 38 Coloxyl .............................................................. 36 Copper............................................................... 36 CT Plus+ .......................................................... 39 Cyclizine lactate ..................................... 23, 38, 39 Cyproheptadine hydrochloride ............................ 37 D Dacarbazine ........................................... 34, 35, 39 Danthron with poloxamer.................................... 42 Dapa-Tabs ......................................................... 42 Diabur 5000 ....................................................... 36 Diastix ............................................................... 36 Diazepam........................................................... 30 Docusate sodium ............................................... 36 Dr Reddy’s Quetiapine ........................................ 43 Dr Reddy’s Risperidone...................................... 43 E EMLA........................................................... 33, 40 Ethambutol hydrochloride ....................... 27, 33, 39 F Fluorescite ......................................................... 42 Fluorouracil Ebewe ....................................... 34, 40 Fluorouracil sodium.......................... 23, 34, 36, 40 Fluox.................................................................. 38 Fluoxetine hydrochloride ..................................... 38 Flutamide ..................................................... 34, 40 Flutamin ....................................................... 34, 40 Fosamax ............................................................ 28 Fosamax Plus .............................................. 28, 36 Frusemide-Claris .......................................... 21, 40 Furosemide ............................................ 21, 40, 42 G Gabapentin (neurontin) ....................................... 33 Glucobay ........................................................... 24 Glucose oxidase................................................. 36 Glycerol ....................................................... 34, 38 H Haloperidol .................................................. 33, 40 Hydrocortisone ............................................ 32, 40 Hydrocortisone butyrate with chlorquinaldol........ 38 Hydrocortisone with cinchocaine ........................ 42 Hypam ............................................................... 31 Hypnovel ........................................................... 31 I Ibuprofen ........................................................... 33 Imuprine ............................................................ 42 Imuran ............................................................... 42 Indomethacin ..................................................... 43 Insulin glulisine ...................................... 21, 40, 43 Intal Spincaps .................................................... 34 Interferon alpha-2a ............................................. 28 Indapamide ........................................................ 42 Ioscan ............................................................... 42

Index

Pharmaceuticals and brands Ipratropium bromide ........................................... 43 Isotretinoin ......................................................... 26 J Jadelle ............................................................... 43 K Keppra ............................................................... 38 Ketone blood beta-ketone electrodes .................. 43 Ketovite ............................................................. 36 Ketovite Liquid ................................................... 36 Konsyl-D...................................................... 21, 41 L Levetiracetam .................................................... 38 Levonorgestrel ................................................... 43 Lignocaine ............................................. 29, 35, 43 Lignocaine hydrochloride ................. 23, 29, 33, 40 Lignocaine hydrochloride with adrenaline............ 40 Lignocaine with chlorhexidine ....................... 29, 35 Lignocaine with prilocaine ............................ 33, 40 Lipitor .................................................... 26, 32, 39 Locoid C ............................................................ 38 Lorazepam ......................................................... 30 Lormetazepam ................................................... 31 Lorstat 10 .................................................... 36, 42 Lorstat 20 .................................................... 36, 42 Lorstat 40 .................................................... 36, 42 Lorstat 80 .................................................... 36, 42 M m-Eslon ....................................................... 33, 41 Malathion ........................................................... 27 Marcain Heavy ................................................... 36 Marcain Isobaric ................................................ 36 Meloxicam ......................................................... 21 Mesna ............................................. 23, 34, 36, 40 Methadone hydrochloride ................................... 43 Methatabs .......................................................... 43 Methotrexate .......................................... 34, 35, 41 Methylergometrine ............................................. 38 Micolette ............................................................ 43 Midazolam ......................................................... 31 Mitomycin C ...................................................... 41 Moduretic .................................................... 26, 32 Morphine sulphate........................................ 33, 41 Morphine tartrate .................................... 33, 35, 41 Mucilaginous laxatives ................................. 21, 41 Multivitamins ............................................... 24, 36 Myambutol............................................. 27, 33, 39 N Naropin .............................................................. 41 Nausicalm.................................................... 23, 39 Navoban ............................................................ 30 Nedocromil ........................................................ 34 Neurontin ........................................................... 33 Nilstat .......................................................... 33, 41 Nitrados ............................................................. 31 Nitrazepam......................................................... 31 Noctamid ........................................................... 31 Normison ........................................................... 31 Nuelin ................................................................ 34 Nystatin ....................................................... 33, 41 O Oil in water emulsion .......................................... 41 Ondansetron ...................................................... 30 Optium Blood Ketone Test Strips ........................ 43 Oratane .............................................................. 26 Ox-Pam ............................................................. 30 Oxazepam .......................................................... 30 P Pacific Buspirone ............................................... 30 Paediatric Seravit ............................................... 24 Periactin ............................................................ 37 Phenate ............................................................. 42 Phenoxymethylpenicillin (penicillin v) ............ 32, 41 Phentolamine mesylate ...................................... 41 Phenylephrine hydrochloride with zinc sulphate .. 37 Plavix ................................................................. 24 Pinorax Forte ...................................................... 42 Pioglitazone ....................................................... 24 Pizaccord........................................................... 24 Prilocaine hydrochloride ..................................... 41 Proctosedyl........................................................ 42 Q Quetiapine.......................................................... 43 R Ranbaxy Amoxicillin ........................................... 36 Regitine ............................................................. 41 Retinol palmitate ................................................ 41 Rexacrom .......................................................... 23 Risperidone........................................................ 43 Roferon-A .......................................................... 28 Ropivacaine hydrochloride with fentanyl ............. 41 S Serenace ..................................................... 33, 40 Sodibic ........................................................ 21, 41 Sodium bicarbonate ..................................... 21, 41 Sodium chloride ........................................... 32, 42 Sodium citrate with sodium lauryl sulphoacetate ........................................ 43 Sodium citro-tartrate .......................................... 32 Sodium cromoglycate .................................. 23, 34 Sodium diotrizoate ............................................. 42 Sodium fluorescein ............................................ 42 Soft white paraffin with paraffin liquid ................. 42 Solu-Cortef .................................................. 32, 40 Suprefact ........................................................... 36

Index

Pharmaceuticals and brands T Tamsulosin hydrochloride .................................. 43 Tamsulosin-Rex ................................................. 43 Temazepam ....................................................... 31 Tenoxicam ......................................................... 21 Theophylline ...................................................... 34 Tilade................................................................. 34 Triazolam ........................................................... 31 Triclosan............................................................ 27 Tropisetron ........................................................ 30 U Univent .............................................................. 43 Ural.................................................................... 32 Urex Forte .......................................................... 42 Uromitexan .................................................. 34, 40 V Valoid (AFT) ....................................................... 38 Veracol ........................................................ 21, 39 Vicrom ............................................................... 34 Vitala-C .............................................................. 42 Vitamin B complex ............................................. 21 X Xeloda ............................................................... 31 Xylocaine ......................................... 23, 29, 33, 40 Xylocaine Viscous .............................................. 23 Z Zincfrin .............................................................. 37 Zofran ................................................................ 30 Zofran Zydis ....................................................... 30 Zoledronic acid .................................................. 21 Zopiclone ........................................................... 31

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 September 2010

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 September 2010 Section H cumulative for August and September 2010 Contents Summary of PHARMAC decisions effective 1 September 2010 …. 3 Atorvastatin – Subsidy changes … 6 Clopidogrel – removal…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.